Abstract:Objective To investigate the clinical efficacy of Qinggan Huayu, Huatan Tongluo agent combined with Songling Xuemaikang in the treatment of hypertension (syndrome of liver heat, blood stasis and phlegm turbidity). Methods A total of 194 hypertension patients who received treatment from January 2017 to January 2018 were selected and divided into treatment group (n=98) and control group (n=96).The treatment group was treated with Qinggan Huayu, Huatan Tongluo agent combined with Songling Xuemaikang, while the control group was treated with nifedipine controlled-release tablets.The 24-hour mean arterial pressure, blood pressure variability, and TCM syndrome score of the two groups were analyzed. Results After treatment, the 24hSBP of the treatment group was significantly lower than that of the control group (P<0.05), but there was no significant difference between the two groups in 24hDBP(P>0.05).The dSSD of the treatment group was significantly lower than that of the control group (P<0.05), but there was no significant difference between the two groups in dDSD, nSSD and nDSD (P>0.05).The 24hSSD, 24hDSD of the treatment group were significantly lower than that of the control group (P<0.05).The total score of TCM symptoms in the treatment group was significantly lower than that in the control group (P<0.05). Conclusion Qinggan Huayu, Huatan Tongluo agents combined with Songling Xuemaikang can effectively reduce 24 h mean systolic blood pressure, reduce blood pressure variability and improve symptoms.